ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August2, 2017, OncoMed Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is located on the Company’s website at www.oncomed.com under “For Investors – Press Releases.”

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by referencetherein.

Item 2.02. Financial Statements and Exhibits.






Press release

OncoMed Pharmaceuticals Inc Exhibit
EX-99.1 2 omed-ex991_8.htm EX-99.1 omed-ex991_8.htm Exhibit 99.1       For Immediate Release   OncoMed Announces Second Quarter 2017 Financial Results   Wholly-owned Immuno-oncology Candidate GITRL-Fc to enter clinic in 2H 2017   Q2 Cash Balance of $129.8M – Cash Through Q3 2019   Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT   REDWOOD CITY,…
To view the full exhibit click here


OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

An ad to help with our costs